The result from first patient dosed with 212Pb-VMT-α-NET in India on a compassionate use basis showed favorable responses after the first dose.
The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated encouraging results after a single low dose of 212Pb-VMT-α-NET.

“The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company’s core brachytherapy business lack of orders from our largest customer and post-COVID recovery efforts resulted in a sales decline.

New tagline: “Treating cancers from the inside out”
New corporate website https://www.perspectivetherapeutics.com
New NYSE American stock ticker symbol to be CATX, effective February 21, 2023…..

Outgoing Isoray CEO Lori Woods said, “This merger represents an important milestone for Isoray. The merger with Viewpoint Molecular Targeting demonstrates our commitment to build on our shared belief of treating cancers from the inside out while providing personalized targeted treatment options for cancer patients…

The stockholders approved Proposal One which amends the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares….

The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1…..

The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1.

Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. “The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders….

To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002.

The presentation will provide an overview of Viewpoint’s pipeline along with a review of data presented at this year’s European Association of Nuclear Medicine conference which concludes on October 19 in Barcelona, Spain.